GGrantIndex
← Leaderboards

Susana T Valente

University Of Florida

$35,884,894
Attributed
$59,291,972
Total exposure
20
Grants
17
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $9.5M · FY201025
$10M$7.5M$5M$2.5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$59,291,972 · 20

By mechanism

UM1$27,293,591 · 1
R01$21,285,621 · 8
R33$3,452,021 · 2
R61$2,830,994 · 1
R37$1,555,260 · 1
R21$1,550,044 · 3

Most similar at University Of Florida

Same institution · by research overlap

Others in their field

Top investigators on “Hiv-1

Research focus

Hiv-1CellsCortistatinViralVirusGenetic TranscriptionCd4 Positive T LymphocytesIn VitroMediatingAntiretroviral TherapyPharmaceutical PreparationsViral ProteinsResidual StateBaseViral ReboundPromoterInsightEpigenetic ProcessPreventMouse ModelToxic EffectInterruptionProductionVirus Replication

Grant awards (64)

HOPE - HIV Obstruction by Programmed Epigenetics$4,951,244
UM1 · FY2025 · AI
Therapeutic Disruption of HIV Transcription by HIV-1 Tat Protein-Degrading Molecules$1,016,887
R01 · FY2025 · AI · contact PI
Evaluation of didehydro-Cortistatin A as a block-and-lock agent for a functional HIV cure in a macaque model$835,797
R01 · FY2025 · AI · contact PI
Exploration of novel block-and-lock agents alone and in combination for HIV remission in humanized mice$835,484
R01 · FY2025 · AI · contact PI
Host factors regulating HIV latency and reactivation$468,510
R37 · FY2025 · AI · contact PI
HOPE - HIV Obstruction by Programmed Epigenetics$5,336,026
UM1 · FY2024 · AI
Exploration of novel block-and-lock agents alone and in combination for HIV remission in humanized mice$889,277
R01 · FY2024 · AI · contact PI
Evaluation of didehydro-Cortistatin A as a block-and-lock agent for a functional HIV cure in a macaque model$847,878
R01 · FY2024 · AI · contact PI
Host factors regulating HIV latency and reactivation$483,000
R37 · FY2024 · AI · contact PI
Development of Brain Organoids to Study the Impact of HIV-1, Drugs of Abuse and Aging on Cognitive Impairment$1
R01 · FY2024 · DA
HOPE - HIV Obstruction by Programmed Epigenetics$6,334,269
UM1 · FY2023 · AI
Exploration of novel block-and-lock agents alone and in combination for HIV remission in humanized mice$903,157
R01 · FY2023 · AI · contact PI
Development of Brain Organoids to Study the Impact of HIV-1, Drugs of Abuse and Aging on Cognitive Impairment$737,501
R01 · FY2023 · DA
Host factors regulating HIV latency and reactivation$483,000
R37 · FY2023 · AI · contact PI
HOPE - HIV Obstruction by Programmed Epigenetics$5,336,026
UM1 · FY2022 · AI
Mode of action of a new Tat HIV-1 inhibitor$1,026,652
R01 · FY2022 · AI · contact PI
Identification and characterization of chromatin regulators of HIV-1 latency$921,796
R33 · FY2022 · AI · contact PI
Evaluation of didehydro-Cortistatin A as a block-and-lock agent for a functional HIV cure in a macaque model$835,133
R01 · FY2022 · AI · contact PI
Development of Brain Organoids to Study the Impact of HIV-1, Drugs of Abuse and Aging on Cognitive Impairment$736,183
R01 · FY2022 · DA
Development and characterization of HIV-1 Tat degraders$300,000
R41 · FY2022 · AI · contact PI
Validation and characterization of Tat inhibitors identified through HTS$231,250
R21 · FY2022 · AI · contact PI
Host factors regulating HIV latency and reactivation$120,750
R37 · FY2022 · AI · contact PI
Host factors regulating HIV latency and reactivation$1
R01 · FY2022 · AI · contact PI
HOPE - HIV Obstruction by Programmed Epigenetics$5,336,026
UM1 · FY2021 · AI
Development of Brain Organoids to Study the Impact of HIV-1, Drugs of Abuse and Aging on Cognitive Impairment$734,866
R01 · FY2021 · DA
Identification and characterization of chromatin regulators of HIV-1 latency$487,375
R33 · FY2021 · AI · contact PI
Host factors regulating HIV latency and reactivation$462,500
R56 · FY2021 · AI · contact PI
Mode of action of a new Tat HIV-1 inhibitor$458,821
R01 · FY2021 · AI · contact PI
Evaluation of didehydro-Cortistatin A as a block-and-lock agent for a functional HIV cure in a macaque model$450,949
R01 · FY2021 · AI · contact PI
Evaluation of didehydro-Cortistatin A as a block-and-lock agent for a functional HIV cure in a macaque model$441,149
R01 · FY2021 · AI · contact PI
Identification and characterization of chromatin regulators of HIV-1 latency$437,889
R33 · FY2021 · AI · contact PI
Mode of action of a new Tat HIV-1 inhibitor$292,298
R01 · FY2021 · AI · contact PI
Validation and characterization of Tat inhibitors identified through HTS$141,939
R21 · FY2021 · AI · contact PI
Validation and characterization of Tat inhibitors identified through HTS$135,561
R21 · FY2021 · AI · contact PI
Identification and characterization of chromatin regulators of HIV-1 latency$930,994
R61 · FY2020 · AI · contact PI
Development of Brain Organoids to Study the Impact of HIV-1, Drugs of Abuse and Aging on Cognitive Impairment$750,923
R01 · FY2020 · DA
Mode of action of a new Tat HIV-1 inhibitor$750,426
R01 · FY2020 · AI · contact PI
Identification and characterization of chromatin regulators of HIV-1 latency$950,000
R61 · FY2019 · AI · contact PI
Mode of action of a new Tat HIV-1 inhibitor$750,426
R01 · FY2019 · AI · contact PI
Towards HIV eradication using a novel Tat inhibitor$450,960
R01 · FY2019 · AI · contact PI
Identification and characterization of chromatin regulators of HIV-1 latency$950,000
R61 · FY2018 · AI · contact PI
Mode of action of a new Tat HIV-1 inhibitor$772,927
R01 · FY2018 · AI · contact PI
Suppressing the latent reservoir with a Tat inhibitor$530,710
R33 · FY2018 · AI · contact PI
Towards HIV eradication using a novel Tat inhibitor$450,960
R01 · FY2018 · AI · contact PI
Suppressing the latent reservoir with a Tat inhibitor$514,330
R33 · FY2017 · AI · contact PI
Towards HIV eradication using a novel Tat inhibitor$450,960
R01 · FY2017 · AI · contact PI
Mode of action of a new Tat HIV-1 inhibitor$654,260
R01 · FY2016 · AI · contact PI
Suppressing the latent reservoir with a Tat inhibitor$559,921
R33 · FY2016 · AI · contact PI
Towards HIV eradication using a novel Tat inhibitor$450,960
R01 · FY2016 · AI · contact PI
Structural/biophysical characterization of a potent HIV transcription inhibitor$211,672
R21 · FY2016 · AI · contact PI
Mode of action of a new Tat HIV-1 inhibitor$885,354
R01 · FY2015 · AI · contact PI
Towards HIV eradication using a novel Tat inhibitor$473,960
R01 · FY2015 · AI · contact PI
Structural/biophysical characterization of a potent HIV transcription inhibitor$305,672
R21 · FY2015 · AI · contact PI
Suppressing the latent reservoir with a Tat inhibitor$268,800
R21 · FY2015 · AI · contact PI
Mode of action of a new Tat HIV-1 inhibitor$678,760
R01 · FY2014 · AI · contact PI
Targeting HIV Capsid Assembly$495,000
R01 · FY2014 · AI · contact PI
Transcriptional silencing of latent HIV infection - a novel small molecule class$291,941
R43 · FY2014 · AI
Suppressing the latent reservoir with a Tat inhibitor$255,150
R21 · FY2014 · AI · contact PI
Mode of action of a new Tat HIV-1 inhibitor$599,646
R01 · FY2013 · AI · contact PI
Targeting HIV Capsid Assembly$465,300
R01 · FY2013 · AI · contact PI
Mode of action of a new Tat HIV-1 inhibitor$667,765
R01 · FY2012 · AI · contact PI
Targeting HIV Capsid Assembly$495,000
R01 · FY2012 · AI · contact PI
Human cellular factors restricting HIV replication$108,000
K22 · FY2011 · AI · contact PI
Human cellular factors restricting HIV replication$162,000
K22 · FY2010 · AI · contact PI